Natera Inc.
(NASDAQ:NTRA) said Japan's Ministry of Health, Labour and Welfare approved its Signatera molecular residual disease (MRD) test for patients with colorectal cancer in the adjuvant setting, making it the first PMDA-approved MRD test in the country.
The precision medicine company expects to launch Signatera commercially in Japan by the end of 2026, pending final pricing decisions.
The approval marks a key milestone in Natera's international oncology expansion.
More than 150,000 people are diagnosed with colorectal cancer each year in Japan, making it one of the country's most common cancers and highlighting the need for personalized treatment strategies.
